109 related articles for article (PubMed ID: 24242215)
1. Multiple myeloma recurrence with optic nerve infiltration diagnosed by vitrectomy, immunohistochemistry, and in situ hybridization.
Nugent AK; Paulus YM; Chan A; Kim JW; Schwartz EJ; Moshfeghi DM
Eur J Ophthalmol; 2014; 24(3):446-8. PubMed ID: 24242215
[TBL] [Abstract][Full Text] [Related]
2. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
[TBL] [Abstract][Full Text] [Related]
4. Chronic Myelogenous Leukemia Relapse Presenting With Central Nervous System Blast Crisis and Bilateral Optic Nerve Infiltration.
Mbekeani JN; Abdel Fattah M; Al Nounou RM; Chebbo W; Dogar MA
J Neuroophthalmol; 2016 Mar; 36(1):73-7. PubMed ID: 26628337
[TBL] [Abstract][Full Text] [Related]
5. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
[No Abstract] [Full Text] [Related]
6. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
[TBL] [Abstract][Full Text] [Related]
7. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
Grannis CH; Dewan VN; Wang RC
Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
[TBL] [Abstract][Full Text] [Related]
8. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic features of multiple myeloma involving the optic nerves.
Yeung SN; Paton KE; Dorovini-Zis K; Chew JB; White VA
J Neuroophthalmol; 2008 Mar; 28(1):12-6. PubMed ID: 18347452
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D
Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706
[TBL] [Abstract][Full Text] [Related]
13. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
15. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
Moreau P; Cavallo F; Leleu X; Hulin C; Amiot M; Descamps G; Facon T; Boccadoro M; Mignard D; Harousseau JL
Leukemia; 2011 May; 25(5):872-4. PubMed ID: 21321571
[No Abstract] [Full Text] [Related]
16. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
[No Abstract] [Full Text] [Related]
17. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
18. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
19. [Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
Fujimi A; Hashimoto A; Kanisawa Y; Okuda T; Minami S; Doi T; Matsuno T; Ishikawa K; Uemura N
Rinsho Ketsueki; 2013 Feb; 54(2):224-8. PubMed ID: 23470832
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Sezer O; Vesole DH; Singhal S; Richardson P; Stadtmauer E; Jakob C; Boral AL; Esseltine DL; Mehta J
Clin Lymphoma Myeloma; 2006 Nov; 7(3):233-5. PubMed ID: 17229340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]